Compare AstraZeneca plc (AZN) vs Blackstone Inc (BX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Blackstone Inc — how do they compare? AstraZeneca plc trades at $158.56 (market cap $248.14B), while Blackstone Inc trades at $145.63 (market cap $117.44B). The key difference: AstraZeneca plc is far larger — about 2.1× Blackstone Inc's market cap, and Blackstone Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| AZN | BX | |
|---|---|---|
Market Cap | $248.14B | $117.44B |
Sector | Health | Financials |
52-Week High | $209.48 | $188.68 |
52-Week Low | $147.06 | $102.12 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Blackstone (BX) trades at $145.65, up 2.81% today, with strong technical momentum showing bullish moving averages and approaching resistance at $147. The company demonstrates robust fundamentals with revenue growth from $10.9B in 2024 to $12.4B in 2025 and net income margin of 25.85%. Recent acquisitions including the Aeroplan stake and HSBC's Australian loan portfolio highlight strategic expansion.
Outlook remains positive with analyst consensus at Buy (63%) and $144 price target, though RSI levels suggest potential overbought conditions. Key risks include private credit market strain and integration challenges from recent acquisitions. Earnings consistency with three consecutive beats supports the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
